Macrogenics Cmn (MGNX) 29.64 $MGNX MacroGenics
Post# of 273257
Posted On: 09/03/2016 7:16:11 AM
Macrogenics Cmn (MGNX) 29.64 $MGNX
MacroGenics to Participate in Two Upcoming Investor Conferences
GlobeNewswire - Wed Aug 31, 6:30AM CDT
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that the Company's management will participate in two upcoming investor conferences. These two conferences include:
MGNX: 29.64 (-0.41)
MacroGenics Provides Update on Corporate Progress and Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 03, 3:16PM CDT
-- MGD010 Phase 1 clinical DART(R) data presented at EULAR
MGNX: 29.64 (-0.41)
Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:35AM CDT
Medical has been a stand out performer so far in Q2.
MGNX: 29.64 (-0.41), INSY: 14.63 (+0.27), CSII: 24.69 (+0.24), BIO: 151.14 (+1.65), CNAT: 1.84 (-0.02)
MacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call
GlobeNewswire - Wed Jul 27, 3:30PM CDT
MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 3, 2016, the Company will release its financial results for the quarter ended June 30, 2016. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Wednesday, August 3, 2016 at 4:30 pm (ET). The call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the passcode 54065731.
MGNX: 29.64 (-0.41)
MacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2016)
GlobeNewswire - Fri Jun 10, 5:00AM CDT
Bispecific molecule based on DART(R) platform simultaneously targets B-cell antigens, CD32B and CD79B
MGNX: 29.64 (-0.41)
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop New DART Molecule for Treatment of Cancer
GlobeNewswire - Wed May 18, 5:00AM CDT
-- MacroGenics licenses MGD015 to Janssen
MGNX: 29.64 (-0.41)
MacroGenics to Present MGD010 Clinical Data at EULAR 2016
GlobeNewswire - Wed May 11, 3:35PM CDT
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that clinical data from its Phase 1a study of MGD010 will be presented at the Annual European Congress of Rheumatology (EULAR 2016), which is being held from June 8 to June 11, 2016 in London, England.
MGNX: 29.64 (-0.41)
First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics
GlobeNewswire - Tue May 10, 6:30AM CDT
MacroGenics, Inc. (Nasdaq: MGNX) today announced that its collaboration partner, Pfizer Inc. (NYSE: PFE), has advanced a bispecific antibody therapeutic candidate generated by MacroGenics' Dual-Affinity Re-Targeting, or DART(R), platform. Pfizer recently dosed a first patient in the Phase 1 clinical study of PF-06671008, which targets P-cadherin and CD3. Increased levels of the protein P-cadherin have been reported in various tumors, including breast, ovarian, endometrial, colorectal and pancreatic cancers, and is correlated with poor survival of patients. The commencement of the Phase 1 study triggers a $2 million milestone payment to MacroGenics under the companies' October 2010 agreement.
MGNX: 29.64 (-0.41), PFE: 34.77 (+0.09)
MacroGenics Provides Update on Corporate Progress and First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:01PM CDT
-- Eight molecules in clinical development, including six in immuno-oncology
MGNX: 29.64 (-0.41)
MacroGenics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Wed May 04, 6:30AM CDT
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO, will present a corporate overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV. The presentation will take place on Wednesday, May 11, 2016 at 5:00 p.m. Pacific Time.
MGNX: 29.64 (-0.41)
MacroGenics Announces Date of First Quarter 2016 Financial Results Conference Call
GlobeNewswire - Wed Apr 27, 3:30PM CDT
MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, May 4, 2016, the Company will release its financial results for the quarter ended March 31, 2016. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Wednesday, May 4, 2016 at 4:30 pm (ET). The call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the passcode 97025319.
MGNX: 29.64 (-0.41)
MacroGenics Presents Data from Five Preclinical Programs at AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:05AM CDT
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the presentation of preclinical data from five programs at the 2016 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana. Four of the five presented posters were from studies based on MacroGenics' Dual-Affinity Re-Targeting, or DART(R), bispecific technology. MacroGenics also presented data from its preclinical anti-B7-H3 antibody-drug conjugate program within the company's B7-H3 franchise.
MGNX: 29.64 (-0.41)
MacroGenics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Thu Feb 04, 5:00PM CST
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at the LEERINK Partners 5th Annual Global Healthcare Conference in New York. The presentation will take place on Thursday, February 11, 2016 at 10:45 a.m. Eastern Time.
MGNX: 29.64 (-0.41)
Global Refractory Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015 - 50 Companies & 117 Drug Profiles
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5gtx2j/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - GlaxoSmithKline Plc - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NantKwest, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Oxford BioTherapeutics Ltd - Synta Pharmaceuticals Corp. - TaiGen Biotechnology Co., Ltd. - Threshold Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/5g...tory_acute
MGNX: 29.64 (-0.41), AMGN: 169.77 (-0.36), EPZM: 7.16 (-0.15), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), CTIC: 0.39 (unch), SNTA: 0.34 (+0.07), ATNM: 1.70 (-0.06), MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), AVEO: 0.90 (-0.01), CALA: 3.08 (unch), ABBV: 64.12 (+0.09), AGIO: 36.35 (-0.39), NVS: 79.38 (+1.11), KPTI: 10.62 (-0.48), CELGZ: 1.18 (+0.05)
Relapsed Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015
M2 - Fri Dec 11, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5bkxtd/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline Plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Novartis AG - Polaris Pharmaceuticals, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/5b...psed_acute
MGNX: 29.64 (-0.41), INCY: 82.02 (+1.21), AMGN: 169.77 (-0.36), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), CTIC: 0.39 (unch), VSTM: 1.33 (-0.01), SNTA: 0.34 (+0.07), ATNM: 1.70 (-0.06), MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), CALA: 3.08 (unch), ABBV: 64.12 (+0.09), AGIO: 36.35 (-0.39), NVS: 79.38 (+1.11), KPTI: 10.62 (-0.48), EXEL: 11.54 (+0.19), CELGZ: 1.18 (+0.05)
Worldwide Esophageal Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 07, 10:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/kppx92/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adaptimmune Limited - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Boehringer Ingelheim GmbH - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Genmab A/S - Glycotope GmbH - Hutchison MediPharma Limited - Ignyta, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - MacroGenics, Inc. - Mebiopharm Co., Ltd. - MedImmune, LLC - Novartis AG - Omeros Corporation - Pfizer Inc. - Precision Biologics, Inc. - Proteo, Inc. - Puma Biotechnology, Inc. - Shionogi & Co., Ltd. - Spectrum Pharmaceuticals, Inc. - Symphogen A/S - Virocan Therapeutics Private Limited - Zhejiang BetaPharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/kp...eal_cancer
MGNX: 29.64 (-0.41), CLRB: 2.16 (+0.02), ADXS: 11.52 (-0.26), PFE: 34.77 (+0.09), CLDX: 3.35 (-0.01), ARQL: 1.40 (unch), AMGN: 169.77 (-0.36), SPPI: 5.24 (-0.05), OMER: 11.10 (+0.34), JNJ: 119.32 (+0.24), RXDX: 5.90 (+0.02), AZN: 33.31 (+0.71), AVEO: 0.90 (-0.01), PBYI: 57.48 (-1.23), NVS: 79.38 (+1.11), KPTI: 10.62 (-0.48), ARRY: 3.50 (-0.02), CELGZ: 1.18 (+0.05)
MacroGenics to Present at the Oppenheimer 26th Annual Healthcare Conference
GlobeNewswire - Wed Dec 02, 3:30PM CST
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at the Oppenheimer 26 Annual Healthcare Conference in New York. The Company's presentation will take place on Wednesday, December 9, 2015 at 1:35 p.m. ET.
MGNX: 29.64 (-0.41)
Data from MacroGenics' Ongoing Phase 1 Study of Enoblituzumab (MGA271) Presented at 30th Annual SITC Meeting 2015
GlobeNewswire - Sat Nov 07, 11:15AM CST
-- Anti-B7-H3 antibody is well-tolerated
MGNX: 29.64 (-0.41)
Publication in PLOS Pathogens Shows the Potential of DART(R) Molecules for HIV Reservoir Elimination Strategy
GlobeNewswire - Thu Nov 05, 3:30PM CST
-- Second paper published demonstrating DART molecule potential against HIV
MGNX: 29.64 (-0.41)
MacroGenics to Participate in Two Upcoming Investor Conferences
GlobeNewswire - Wed Aug 31, 6:30AM CDT
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that the Company's management will participate in two upcoming investor conferences. These two conferences include:
MGNX: 29.64 (-0.41)
MacroGenics Provides Update on Corporate Progress and Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 03, 3:16PM CDT
-- MGD010 Phase 1 clinical DART(R) data presented at EULAR
MGNX: 29.64 (-0.41)
Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:35AM CDT
Medical has been a stand out performer so far in Q2.
MGNX: 29.64 (-0.41), INSY: 14.63 (+0.27), CSII: 24.69 (+0.24), BIO: 151.14 (+1.65), CNAT: 1.84 (-0.02)
MacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call
GlobeNewswire - Wed Jul 27, 3:30PM CDT
MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 3, 2016, the Company will release its financial results for the quarter ended June 30, 2016. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Wednesday, August 3, 2016 at 4:30 pm (ET). The call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the passcode 54065731.
MGNX: 29.64 (-0.41)
MacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2016)
GlobeNewswire - Fri Jun 10, 5:00AM CDT
Bispecific molecule based on DART(R) platform simultaneously targets B-cell antigens, CD32B and CD79B
MGNX: 29.64 (-0.41)
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop New DART Molecule for Treatment of Cancer
GlobeNewswire - Wed May 18, 5:00AM CDT
-- MacroGenics licenses MGD015 to Janssen
MGNX: 29.64 (-0.41)
MacroGenics to Present MGD010 Clinical Data at EULAR 2016
GlobeNewswire - Wed May 11, 3:35PM CDT
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that clinical data from its Phase 1a study of MGD010 will be presented at the Annual European Congress of Rheumatology (EULAR 2016), which is being held from June 8 to June 11, 2016 in London, England.
MGNX: 29.64 (-0.41)
First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics
GlobeNewswire - Tue May 10, 6:30AM CDT
MacroGenics, Inc. (Nasdaq: MGNX) today announced that its collaboration partner, Pfizer Inc. (NYSE: PFE), has advanced a bispecific antibody therapeutic candidate generated by MacroGenics' Dual-Affinity Re-Targeting, or DART(R), platform. Pfizer recently dosed a first patient in the Phase 1 clinical study of PF-06671008, which targets P-cadherin and CD3. Increased levels of the protein P-cadherin have been reported in various tumors, including breast, ovarian, endometrial, colorectal and pancreatic cancers, and is correlated with poor survival of patients. The commencement of the Phase 1 study triggers a $2 million milestone payment to MacroGenics under the companies' October 2010 agreement.
MGNX: 29.64 (-0.41), PFE: 34.77 (+0.09)
MacroGenics Provides Update on Corporate Progress and First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:01PM CDT
-- Eight molecules in clinical development, including six in immuno-oncology
MGNX: 29.64 (-0.41)
MacroGenics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Wed May 04, 6:30AM CDT
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO, will present a corporate overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV. The presentation will take place on Wednesday, May 11, 2016 at 5:00 p.m. Pacific Time.
MGNX: 29.64 (-0.41)
MacroGenics Announces Date of First Quarter 2016 Financial Results Conference Call
GlobeNewswire - Wed Apr 27, 3:30PM CDT
MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, May 4, 2016, the Company will release its financial results for the quarter ended March 31, 2016. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Wednesday, May 4, 2016 at 4:30 pm (ET). The call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the passcode 97025319.
MGNX: 29.64 (-0.41)
MacroGenics Presents Data from Five Preclinical Programs at AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:05AM CDT
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the presentation of preclinical data from five programs at the 2016 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana. Four of the five presented posters were from studies based on MacroGenics' Dual-Affinity Re-Targeting, or DART(R), bispecific technology. MacroGenics also presented data from its preclinical anti-B7-H3 antibody-drug conjugate program within the company's B7-H3 franchise.
MGNX: 29.64 (-0.41)
MacroGenics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Thu Feb 04, 5:00PM CST
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at the LEERINK Partners 5th Annual Global Healthcare Conference in New York. The presentation will take place on Thursday, February 11, 2016 at 10:45 a.m. Eastern Time.
MGNX: 29.64 (-0.41)
Global Refractory Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015 - 50 Companies & 117 Drug Profiles
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5gtx2j/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - GlaxoSmithKline Plc - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NantKwest, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Oxford BioTherapeutics Ltd - Synta Pharmaceuticals Corp. - TaiGen Biotechnology Co., Ltd. - Threshold Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/5g...tory_acute
MGNX: 29.64 (-0.41), AMGN: 169.77 (-0.36), EPZM: 7.16 (-0.15), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), CTIC: 0.39 (unch), SNTA: 0.34 (+0.07), ATNM: 1.70 (-0.06), MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), AVEO: 0.90 (-0.01), CALA: 3.08 (unch), ABBV: 64.12 (+0.09), AGIO: 36.35 (-0.39), NVS: 79.38 (+1.11), KPTI: 10.62 (-0.48), CELGZ: 1.18 (+0.05)
Relapsed Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015
M2 - Fri Dec 11, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5bkxtd/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline Plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Novartis AG - Polaris Pharmaceuticals, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/5b...psed_acute
MGNX: 29.64 (-0.41), INCY: 82.02 (+1.21), AMGN: 169.77 (-0.36), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), CTIC: 0.39 (unch), VSTM: 1.33 (-0.01), SNTA: 0.34 (+0.07), ATNM: 1.70 (-0.06), MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), CALA: 3.08 (unch), ABBV: 64.12 (+0.09), AGIO: 36.35 (-0.39), NVS: 79.38 (+1.11), KPTI: 10.62 (-0.48), EXEL: 11.54 (+0.19), CELGZ: 1.18 (+0.05)
Worldwide Esophageal Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 07, 10:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/kppx92/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adaptimmune Limited - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Boehringer Ingelheim GmbH - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Genmab A/S - Glycotope GmbH - Hutchison MediPharma Limited - Ignyta, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - MacroGenics, Inc. - Mebiopharm Co., Ltd. - MedImmune, LLC - Novartis AG - Omeros Corporation - Pfizer Inc. - Precision Biologics, Inc. - Proteo, Inc. - Puma Biotechnology, Inc. - Shionogi & Co., Ltd. - Spectrum Pharmaceuticals, Inc. - Symphogen A/S - Virocan Therapeutics Private Limited - Zhejiang BetaPharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/kp...eal_cancer
MGNX: 29.64 (-0.41), CLRB: 2.16 (+0.02), ADXS: 11.52 (-0.26), PFE: 34.77 (+0.09), CLDX: 3.35 (-0.01), ARQL: 1.40 (unch), AMGN: 169.77 (-0.36), SPPI: 5.24 (-0.05), OMER: 11.10 (+0.34), JNJ: 119.32 (+0.24), RXDX: 5.90 (+0.02), AZN: 33.31 (+0.71), AVEO: 0.90 (-0.01), PBYI: 57.48 (-1.23), NVS: 79.38 (+1.11), KPTI: 10.62 (-0.48), ARRY: 3.50 (-0.02), CELGZ: 1.18 (+0.05)
MacroGenics to Present at the Oppenheimer 26th Annual Healthcare Conference
GlobeNewswire - Wed Dec 02, 3:30PM CST
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at the Oppenheimer 26 Annual Healthcare Conference in New York. The Company's presentation will take place on Wednesday, December 9, 2015 at 1:35 p.m. ET.
MGNX: 29.64 (-0.41)
Data from MacroGenics' Ongoing Phase 1 Study of Enoblituzumab (MGA271) Presented at 30th Annual SITC Meeting 2015
GlobeNewswire - Sat Nov 07, 11:15AM CST
-- Anti-B7-H3 antibody is well-tolerated
MGNX: 29.64 (-0.41)
Publication in PLOS Pathogens Shows the Potential of DART(R) Molecules for HIV Reservoir Elimination Strategy
GlobeNewswire - Thu Nov 05, 3:30PM CST
-- Second paper published demonstrating DART molecule potential against HIV
MGNX: 29.64 (-0.41)
(0)
(0)Scroll down for more posts ▼